Skip to main content
. 2014 Jul 23;5(15):6466–6483. doi: 10.18632/oncotarget.2238

Figure 6. Redirected lysis of CD19-positive malignant cells from primary patient material mediated by triplebody 19-3-19.

Figure 6

The ability of triplebody 19-3-19 to mediate the lysis of malignant cells isolated from the peripheral blood of patients with different B cell malignancies (see Table 3) via allogeneic and autologous effector T cells was assessed in redirected lysis assays. Samples were assayed in triplicate. Error bars indicate intra-sample variation. (A) Specific lysis of malignant cells via allogeneic pre-stimulated effector T cells mediated at different concentrations of the 19-3 BiTE (diamonds) and triplebody 19-3-19 (circles) or the therapeutic antibody MabThera® (triangles) in a 3 hr assay, respectively. Patient 1 (MPAL (NOS)): blue; patient 2 (NHL): red; patient 3 (B-CLL): green; patient 4 (relapsed B-CLL): yellow; and patient 5 (B-CLL): purple. (B) Triplebody 19-3-19-induced depletion of CD19-positive cells by autologous effector T cells and expansion of memory T cells (CD3+ CD45RO+) in the PBMC fraction isolated from patient 2 (NHL) in a 7 d assay. 1 nM of fresh Triplebody 19-3-19 was added every 48 hrs (indicated by asterisks). A similar assay was performed with samples from patients 1 (MPAL (NOS)) and 3 (B-CLL) (data not shown), but no response was observed, possibly due to the relatively short observation time, T cell attenuation or too low initial numbers of effector T cells.